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MicroRNAs (miRNAs) are small noncoding RNAmolecules which are involved in tumorigenesis and development. To investigate
their role in primary laryngeal squamous cell carcinoma (LSCC),miRNAGeneChipswere used to screen the differentially expressed
miRNA, and then validated by real-time quantitative PCR in LSCC samples, we found that miR-375 was frequently downregulated
in primary LSCC tissues. The tumor-suppressive effect of miR-375 was determined by in vitro assays; through gain-of-function
studies we demonstrated that miR-375 can inhibit LSCC cell (SNU-48 and SNU-899) proliferation, motility, and invasion, and
promote their apoptosis. In addition, bioinformatics tools TargetScan, PicTar, and Miranda were used to investigate the potential
target of miR-375; bioinformatics analysis and dual-luciferase reporter assay indicated that IGF1R was a novel direct target of miR-
375. Ectopic transfection of miR-375 led to a significant reduction in IGF1R and its downstream signalingmolecule AKT at both the
mRNA and protein levels in LSCC cells. Our results suggested that downregulation of miR-375 is one of the molecular mechanisms
for the development and progression of LSCC by directly targeting IGF1R and affecting its downstream AKT signaling pathways.
Furthermore, miR-375 and IGF1R may serve as a novel therapeutic target for LSCC.
1. Introduction
Laryngeal carcinoma is one of the most common malignant
neoplasms. With an estimated incidence rate of 5.1/100,000
in males worldwide in 2008, it heavily threatens their health
and quality of life [1, 2]. Squamous cell carcinoma is the
predominant histological type accounting for over 95% of
laryngeal carcinoma. There have been reported changes in
the expression of many oncogenes (Ras [3], ZFX [4], and
Aurora-A [5]) and tumor suppressor genes (BMI1 [6], TSLC1
[3, 7], and p-AKT [8]) in LSCC. These changes could affect
cancer development bymodulating downstream signal trans-
duction pathways such as the well-known AKT signaling
pathway [9, 10]. Therefore, a deeper understanding of these
molecular mechanisms will help us find new diagnostic
and therapeutic approaches to this disease and improve the
prognosis of LSCC patients.
MicroRNA are a class of small noncoding RNAs (20–
25 ribonucleotides) that play an important role in regulating
gene function. Upon binding to the 3󸀠-untranslated region
(UTR) of their targetmessenger RNAs, the expression of their
target gene is repressed or stopped by multiple mechanisms
including enhanced translational repression and mRNA
degradation [11, 12]. Since the relationship between miRNAs
and cancer has been first elucidated in a study of B cell
chronic lymphocytic leukaemia [13], an increasing number of
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studies have shown that the biological functions of miRNAs
are highly correlated with human carcinogenesis of lung,
breast, ovary, and liver, and laryngeal carcinoma is not an
exception [14].These studies suggest a critical role ofmiRNAs
in tumorigenesis and development [15]. Previous studies
have shown several dysregulated miRNAs in LSCC through
expressing array profiling. The target genes of these miRNAs
and the related cancer pathways have been further identified.
For example, miR-1 was downregulated in LSCC tissues and
suppressed the invasion and migration by targeting FN1 in
LSCC cell [16], and miRNA-1297 was originally found to
regulate cell proliferation and differentiation in LSCC by
targeting PTEN [17]. However, further understanding of the
molecular mechanisms of miRNA in LSCC is needed before
providing better therapeutic approach for LSCC patients. In
present study, we aimed at identifying the most aberrantly
expressed miRNA in LSCC tissues, investigating the biologi-
cal functions of this miRNA in LSCC, and further discussing
the underlying mechanisms.
2. Materials and Methods
2.1. Clinical Samples. We obtained paired larynx squamous
cell carcinoma (LSCC) and their corresponding nontumor
tissues (located more than 10mm from the tumors) from 40
patients who underwent primary surgical resection of LSCC
between March 2012 and September 2013 in our department.
All samples were confirmed by pathology. Samples were
snap-frozen in liquid nitrogen after resection and stored at
−80∘C. Patients were excluded if they had recurrent LSCC or
had primary LSCCbut underwent chemoradiotherapy before
surgical operation. This study was approved by the Human
Research Ethics Committee of Sun Yat-sen University (the
ethical number: [2013 23]).
2.2. Gene Expression Microarray. Total RNA was extracted
from LSCC tumor and corresponding nontumor samples
using the mirVana miRNA isolation kit (Ambion). Before
microarray (Affymetrix) analysis, RNA quality was con-
firmed by RNA integrity number using Agilent 2100 bio-
analyzer (Agilent Technologies) at the University of Hong
Kong. All samples had an RNA integrity number greater than
7.0.
2.3. Cell Culture and Transfection. Two LSCC cell lines
(SNU899 and SNU46) were kindly provided by Professor
Thian-Sze Wong (University of Hong Kong). Cells were
maintained in RPMI-1640 (Hyclone) containing 10% fetal
bovine serum (FBS, Hyclone), 100 units/mL penicillin, and
100 𝜇g/mL streptomycin, in a humidified incubator of 5%
CO
2
at 37∘C. The hsa-miR-375 molecule (miR-375 mimics)
and RNA-oligonucleotides negative control (miR-NC) were
obtained from GenePharma corporation. Transfection of
cells was performed usingOligofectamine (Invitrogen, Carls-
bad, CA) according to the manufacturer’s protocol. Culture
medium was changed 24 h after transfection. Transfection
efficiency was evaluated by real-time PCR from three experi-
ments.
2.4. Extraction of Total RNA. Total RNA was isolated from
40 pairs of frozen tissue samples using the mirVana miRNA
Isolation kit (Ambion) according to the manufacturer’s pro-
tocol. For human LSCC cells SNU46 and SNU899, total RNA
was extracted using TRIzol (Invitrogen, Carlsbad, California,
USA).
2.5. Quantitative Reverse Transcription PCR. Quantitative
PCR was carried out in triplicate with primers for miR-
375, U6, IGF1R, and GAPDH using 7900 HT real-time
PCR system (Applied Biosystems) following standard quan-
titative PCR protocol. The primers used were as fol-
lows: miR-375: (F) 5󸀠-CAGGGTCCGAGGTATT-3󸀠 and (R)
5󸀠-CTGCTTTGTTCGTTCG-3󸀠; U6: (F) 5󸀠-CTCGCTTCG-
GCAGCACA-3󸀠 and (R) 5󸀠-AACGCTTCACGAATTTGC-
GT-3󸀠; IGF1R: (F) 5󸀠-AACCCCAAGACTGAGGTGTG-3󸀠
and (R) 5󸀠-TGACATCTCTCCGCTTCCTT-3󸀠; GAPDH: (F)
5󸀠-CCACCCATGGCAAATTCCATGGCA-3󸀠 and (R) 5󸀠-
TCTAGACGGCAGGTCAGGTCCACC-3󸀠.
The expression level was normalized against endogenous
U6 and GAPDH for miR-375 and IGF1R, respectively. qRT-
PCR results were analyzed and expressed as relative gene
expression, which were then converted to fold changes by
2
−ΔΔCt method.
2.6. Proliferation Assay. LSCC cells (105/well) transfected
with miR-375 mimics or miR-NC were seeded into 96-well
plate and cultured for 24, 48, 72, and 96 h. For MTT assay, 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) (0.5mg/mL, pH 4.7; Sigma) was added 4 h before the
end of the culture time. At indicated times, the supernatant
was removed, 150 𝜇L dimethyl sulfoxide (DMSO) was added,
and the plate was shaken for 15 minutes at room temperature.
The absorbance at 490 nm was measured using a microplate
reader (Bio-Rad, Hercules, CA, USA).The mean values from
5 identical wells were used to construct the cell growth value.
2.7. Wound Healing Assay. Transfected cells (105/well) were
cultured in six-well plates for 24 h and then 5 wounds were
made on the cell monolayer using a 20𝜇L pipette tip. Cells
were washed three times with PBS and then cultured in
RPMI-1640. Cells were imaged at 0, 6, 12, and 24 h after the
wounding.The distancemigrated bymiR-375mimics-treated
cells relative to that migrated by miR-NC-treated cells was
determined.
2.8. Invasion Assay. Cell invasion was determined using
transwell invasion chambers (corning). 2 × 104 cells were
seeded on the upper side of the polycarbonate transwell
filter with Matrigel (BD Biosciences) and cultured in 200𝜇L
RPMI-1640.The lower chamberwas filledwith 500 𝜇LRPMI-
1640 with 10% FBS to attract cells. After cells were incubated
for 36 hours at 37∘C and 5% CO
2
, those left on the upper
chamberwere removedwith a cotton swab.Thefilterwas then
fixed with 95% ethanol for 20min. Cells on the bottom of the
filter were stained with 4 g/L crystal violet, photographed in
five independent 20x magnification fields, and counted.
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2.9. Apoptosis Assay. The apoptosis ratio was analyzed using
the Annexin V-FITC Apoptosis Detection Kit (KeyGEN
Biotech, China) according to themanufacturer’s instructions.
Cells (2 × 105) were transfected withmiR-375mimics ormiR-
NC for 48 h and then harvested. Cells were resuspended in
300 𝜇L binding buffer containing Annexin V-FITC and PI
and incubated at room temperature in the dark for 15min.
Stained cells were analyzed by flow cytometry (FACScan;
BD Biosciences) and the percentage of apoptotic cells was
obtained. Samples from three independent experiments were
used for analysis.
2.10. Dual-Luciferase Reporter Assay. A 1572 bp fragment
from the 3󸀠-UTR of the IGF1R gene (containing two potential
miR-375-targeting sites at position 2276 and 2993)was cloned
into the hRlu site of luciferase reporter vector PsiCHECKUM
(Promega, Madison,WI, USA) and the recombinant plasmid
was designated PsiCHECKUM-wt. The site-directed muta-
genesis of miR-375 target site in the 3󸀠-UTR of the IGF1R
gene was performed using the site-directed mutagenesis kit
(TaKaRa,Dalian, China).We created 3 correspondingmutant
constructs by mutating the seed regions of the miR-375
binding sites: PsiCHECKUM-mut1 plasmid contains mutated
binding site at position 2276–2282, PsiCHECKUM-mut2 plas-
mid containsmutated binding site at position 2993–2999, and
PsiCHECKUM-mut3 plasmid contains mutated binding sites
at both positions as mentioned above. The constructs were
verified by sequencing.
SNU-46 cells (2 × 104/well) were seeded into 24-well
plates and cotransfected with 0.5 𝜇g of the luciferase reporter
gene construct and 1𝜇L miRNA mimic or inhibitor (50 𝜇M)
using Lipofectamine 2000 (Invitrogen). After 48 h, Firefly
andRenilla luciferase signalswere determinedusing the dual-
luciferase reporter assay system (Promega) following the
manufacturer’s instructions. The pRL-TK vector (Promega)
was cotransfected as an internal control for the normalization
of the transfection efficiency. Activity of Renilla luciferase
was normalized to Firefly luciferase. Samples were assayed in
triplicate.
2.11.Western Blot Analysis. Cells were collected in lysis buffer,
and proteinwas extracted and analyzed bywestern blotting as
described previously [18]. The antibodies used include anti-
IGF1R antibody (1 : 500; Abcam) and anti-phosphorylated
Akt antibody (Ser473; 1 : 2000; Cell Signaling Technology).
2.12. Statistical Analysis. Statistical analyses were performed
using GraphPad Prism 5 software. Wilcoxon signed-ranks
test was used to analyze the differences inmiRNA expression.
Patients were categorized into groups with high (above
median) or low (below median) miRNA375 expression. The
association of miRNA375 expression with LSCC patients’
clinicopathological features was analyzed by the 𝜒2 test.
Differences were considered significant when the 𝑃 value was
less than 0.05.
3. Results
3.1. miRNA Profiling in Human LSCC. To investigate the role
of miRNAs in LSCC,MicroRNAExpression GeneChips were
used for expression profiling analysis. Differential expression
between LSCC tissues and their corresponding nontumor
tissues was defined using a cutoff value of 5-fold change
(Tables 1 and 2). Among the miRNAs, miR-375 was found
with the largest fold change in expression array and thus was
chosen for further study.
3.2. miR-375 Was Downregulated in LSCC. To further assess
the expression of miR-375, qRT-PCR was conducted on 40
pairs of LSCC tissues. miR-375 expression was notably lower
in cancer tissues compared with their paired paracarcinoma
tissues, similar to the previous miRNA expression array data.
These results indicate that miR-375 expression is reduced in
human LSCC tissues (Figure 1(a)).
3.3. Relationship between miR-375 Expression and Tumor
Clinicopathologic Features. All patients were staged accord-
ing to the 2002 Union Form International Cancer Control
(UICC) staging classification system for laryngeal cancer.The
levels of miR-375 expression in stage III-IV cases were much
lower than those in stage I-II cases, suggesting that miR-375
expression correlated with LSCC malignancy (Figure 1(b)).
We did not find any significant association between the
expression of miR-375 and patient age, gender, nodal status,
pathological grade, and tobacco and alcohol use. Only pT
status (𝑃 = 0.035) and UICC clinical stage (𝑃 = 0.041) were
linked to miR-375 expression (Table 3).
3.4. miR-375 Suppressed LSCC Cell Proliferation. miR-375
was found to be downregulated in LSCC tissues by qRT-PCR,
implicating its potential role in regulating LSCC cells’ biolog-
ical behaviors. To further determine whether miR-375 affects
the proliferation of LSCC cells, miR-375 mimics or miR-NC
were transfected into LSCC cell lines and MTT assay was
performed. Satisfactory transfection efficiency was observed
in these cells, and overexpression of miR-375 significantly
suppressed the proliferation of SNU-46 and SNU-899 cells at
24, 48, 72, and 96 h after transfection, respectively (Figure 2,
𝑃 < 0.05).
3.5. miR-375 Promoted Apoptosis in LSCC Cells. To evaluate
the effect of miR-375 on LSCC cell apoptosis, FACS analysis
for apoptosis was performed using Annexin-V-FITC and
PI dye. The percentage of apoptotic cells was significantly
increased in response to miR-375 overexpression compared
with miR-NC overexpression in SNU46 cells. In SNU899
cells, an increase in apoptotic cells was observed with miR-
375 overexpression compared with miR-NC overexpression.
These results indicated the antiapoptotic role of miR-375 in
LSCC cells (Figure 3).
3.6. miR-375 Inhibited LSCC Cell Migration and Invasion. To
investigate whethermiR-375 overexpression also significantly
reduces the migration and invasion of LSCC cells, wound
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Table 1: Downregulated miRNAs in LSCC tissues.
Downregulated miRNA Sequence Fold change
hsa-miR-375 UUUGUUCGUUCGGCUCGCGUGA 106.9796
hsa-miR-99a AACCCGUAGAUCCGAUCUUGUG 13.27167
hsa-miR-30a UGUAAACAUCCUCGACUGGAAG 11.03537
hsa-miR-574-3p CACGCUCAUGCACACACCCACA 10.9491
hsa-miR-200b UAAUACUGCCUGGUAAUGAUGA 9.396616
hsa-miR-148a UCAGUGCACUACAGAACUUUGU 7.805731
hsa-miR-143 UGAGAUGAAGCACUGUAGCUC 6.750769
hsa-miR-141 UAACACUGUCUGGUAAAGAUGG 5.866387
hsa-let-7f UGAGGUAGUAGAUUGUAUAGUU 5.637025
hsa-miR-200b∗ CAUCUUACUGGGCAGCAUUGGA 5.199535
∗When the two arms of precursor were added to produce mature miRNA separately, according to cloning experiments.
Table 2: Upregulated miRNAs in LSCC tissues.
Upregulated miRNA Sequence Fold change
hsa-miR-205 GUGAAAUGUUUAGGACCACUAG 77.25538
hsa-miR-25 CUCCCACUGCUUCACUUGACUA 33.99586
hsa-miR-193b∗ AACAUUCAUUGCUGUCGGUGGGU 33.9129
hsa-miR-342-5p CUGUGCGUGUGACAGCGGCUGA 20.45821
hsa-miR-185 UAAGGUGCAUCUAGUGCAGAUAG 20.30513
hsa-miR-221 CACUAGAUUGUGAGCUCCUGGA 16.9373
hsa-miR-720 UGCGGGGCUAGGGCUAACAGCA 12.71319
hsa-miR-3178 AACUGGCCCUCAAAGUCCCGCU 12.26441
hsa-miR-181a CAAAGUGCUGUUCGUGCAGGUAG 10.09024
hsa-miR-31 AAUGGAUUUUUGGAGCAGG 9.909428
hsa-miR-345 AAGGAGCUUACAAUCUAGCUGGG 9.848006
hsa-miR-663 AAUGACACGAUCACUCCCGUUGA 9.702424
hsa-miR-193a-5p UAGCUUAUCAGACUGAUGUUGA 9.571058
hsa-miR-1260b GCAGUCCAUGGGCAUAUACAC 8.908698
hsa-miR-99b UAACAGUCUACAGCCAUGGUCG 8.887395
hsa-miR-151-3p UCCUUCAUUCCACCGGAGUCUG 8.517569
hsa-miR-500 CAUUGCACUUGUCUCGGUCUGA 7.33227
hsa-miR-762 CGGGGUUUUGAGGGCGAGAUGA 6.080536
∗When the two arms of precursor were added to produce mature miRNA separately, according to cloning experiments.
healing and transwell invasion assays were conducted. We
found that overexpression of miR-375 led to a decrease in
SNU-46 cell migration (Figure 4) and significantly inhibited
invasion of LSCC cells (Figure 5).These results suggested that
miR-375 contributes to suppress both LSCC cell migration
and invasive capacity in vitro.
3.7. IGF1R Was a Potential Target of miR-375. Given the
observation that miR-375 played an important role in regu-
lating LSCC cells biological properties, we next investigated
the potential targets of miR-375 using bioinformatics tools
TargetScan, PicTar, and Miranda. All of these programs
predicted IGF1R as a target of miR-375. Two potential miR-
375 targeting sites were identified at position 2276 and 2993,
respectively, in IGF1R 3󸀠-UTR (Figure 6(a)). To confirm
the target relationship, four luciferase reporter plasmids
were generated, including the psiCHECK-2-wild-IGF1R-
3󸀠UTR reporter plasmid (wt) with the wild-type IGF1R
target sequence and the psiCHECK-2-mutant-IGF1R-3󸀠UTR
reporter plasmids (mut1, mut2, and mut3) in which the
conserved target sequence at position 2276 and/or 2993 was
mutated. Plasmids mut1, mut2, and mut3 had the mutation
at positions 2276, 2993, and both 2276 and 2993, respec-
tively. The reporter plasmids were cotransfected with miR-
375 mimic or miR-375 inhibitor into SNU-46 cells. miR-
375 significantly inhibited the luciferase activity of wild-type
reporter (wt) plasmid (Figure 6(b)) and partially inhibited
that of the mutant reporter plasmids mut1 and mut2 (Fig-
ures 6(c) and 6(d)). In contrast, the luciferase activity was
not affected by plasmid mut3 (Figure 6(e)), probably due
to the mutation of both miR-375 binding sites in IGF1R
3󸀠UTR. These data indicate that IGF1R was targeted directly
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Figure 1: miR-375 was downregulated in LSCC tissue samples. (a) Expression levels of miR-375 in normal LSCC tissues and paired normal
tissues were analyzed by qRT-PCR and normalized to the levels of U6. (b) Relative expression levels of miR-375 in different stages of cancer
tissues. Forty pairs of samples were divided into two groups according to the patient’s clinic stage. (∗∗∗) Significant differencewhen compared
with normal LSCC tissues (𝑃 < 0.001).
Table 3: Relationship between miR-375 expression and tumor clinicopathologic features.
Characteristic Number of cases miR-375 low level miR-375 high level Values
All samples 40 20 20
Age
≤60 23 11 12 0.749
>60 17 9 8
pT status
Tis-T2 15 3 12 0.744
T3-T4 25 17 8
pN status
N0 28 13 15 0.490
N
>0
12 7 5
Clinical UICC stage
Early stage (I-II) 12 2 10 0.006
Advanced stage (III-IV) 28 18 10
Pathological grade
G1 14 6 8 0.736
G2-G3 26 14 12
Tobacco hobby
No 9 3 6 0.292
Yes 31 17 14
Alcohol hobby
No 19 9 10 0.332
Yes 21 11 10
by miR-375. We then transfected LSCC cell lines with miR-
375 and miR-NC and confirmed the transfection efficiency
using RT-PCR assays. Cells overexpressing miR-375 showed
lower levels of IGF1R protein when compared with nega-
tive control cells (Figure 7). QRT-PCR was performed to
investigate the expression of IGF1R in LSCC tissues; the
result shows that this gene was significantly higher in tumor
tissues than the adjacent normal tissues (Figure 8). Since
IGF1R is a major player in the activation of the Akt signaling
pathway, we also investigated the effect of miR-375 on the
downregulation of Akt phosphorylation. As illustrated in
Figure 9, although total Akt level was constant, the level
of p-Akt was reduced after cells were treated with miR-375
mimic.
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Figure 2: miR-375 overexpression inhibited LSCC cell proliferation. (a) Overexpression of miR-375 decreased SNU-46 cell growth. (b)
Overexpression ofmiR-375 decreased SNU-899 cell growth. (∗∗∗) Significant differencewhen comparedwith the negative-control (miR-NC)
and blank-control (NULL) group (𝑃 < 0.001).
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Figure 3: Apoptosis assay showing induction of apoptosis after miRNA-375 overexpressed by miRNA-375 mimics in SNU46 cells. Early and
late apoptotic cells were combined as annexin V-positive cells that were employed as the criterion to calculate the percentage of cell apoptosis.
(∗) Significant difference when compared with the miR-NC group (𝑃 < 0.05).
4. Discussion
In recent years, with the development of microarrays and
PCR, many studies have suggested that dysregulation of
miRNAs is closely related with tumor development [19–21].
However, these studies did not specify the mechanism of
miRNAs in LSCC. Here we screened miRNAs from LSCC
tissues and corresponding normal laryngeal epithelial tissues
usingmicroarrays and identifiedmiR-375 as themiRNAwith
the most significant change in its expression between LSCC
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Figure 4: miR-375 suppressed LSCC cell migration. Wound healing assay shows that SNU-46 cell motility could be effectively suppressed by
miR-375 mimics (a) and miR-NC (b). Representative images were taken at 0, 12, and 24 h after scratching.
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Figure 5: Transwell invasion assay. (a) Upregulation of miR-375 in SNU-46 cells significantly inhibited invasion compared with the control
group. (b) Invasion of SNU-899 cells was inhibited when cells were transfected with miR-375 mimics compared with miR-NC. Cells on the
bottom of the invasion chamber were fixed, stained, and photographed, and the number of cells was counted. The results are expressed as
mean ± SD of three independent experiments. (∗) Significant difference when compared with the miR-NC group (𝑃 < 0.05).
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Figure 6: miR-375 inhibited the expression of IGF1R by targeting its 3󸀠-UTR. (a) Schematic diagram showing the two potential targeting sites
of miR-375 in the 3󸀠-UTR of IGF1R and gene sequence included in four luciferase reporter plasmids, respectively. (b–e) Relative luciferase
activities of IGF1R-wt and IGF1R-mut reporters were obtained by cotransfection of scrambled control miRNA, miR-375 mimic or miR-375
inhibitor, and psiCHECK-2-IGF1R-3󸀠UTR reporter plasmid and calculated as the ratio of Firefly/Renilla activities and normalized to those
of the control. (∗) Significant difference when compared with the control (𝑃 < 0.05). (∗∗) Significant difference when compared with the
control (𝑃 < 0.01).
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Figure 7: miR-375 inhibited IGF1R expression at both mRNA and protein levels. SNU-46 cells transfected with miR-NC and mi-R375 were
analyzed by RT-PCR (a). Overexpression of miR-375 inhibited IGF1R expression in SNU-46 and SNU-899 cells at the protein level (b).
(∗) Significant difference when compared with the control (𝑃 < 0.05).
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Figure 8: IGF1R was upregulated in LSCC tissue samples. Expres-
sion level of IGF1R was tested in 20 primary LSCC by qRT-PCR.
Results showed that IGF1R was frequently upregulated in tumour
tissues compared with their normal counterparts. GAPDHwas used
as an internal control.
tissues and normal control tissues. We then analyzed 40
pairs of LSCC and normal surrounding tissues using qRT-
PCR for verification and found that miR-375 expression was
significantly lower in LSCC tissues and its level was closely
related to patient’s clinical stage.
These results suggest that miRNA-375 downregulation
may be one of the molecular events for LSCC development.
Originally found in pancreatic tissues, miR-375 is consid-
ered to be an evolutionarily conserved and islet-specific
miRNA that functions as a regulator of insulin secretion
[22]. Subsequent studies have shown that low expression of
miR-375 was observed in many malignancies, such as liver
cancer, esophageal cancer, and head and neck squamous cell
carcinoma [14, 23–25]. Harris et al. have shown that miRNA-
375 expression was significantly lower in the head and neck
squamous cell carcinoma from miRNA expression profiling
[26]. Similar results were also shown by others [25, 27]. miR-
375 inhibits the expression of multiple target genes and is
involved in almost all cell biological processes in cancers,
including cell proliferation, apoptosis, differentiation, migra-
tion, and invasion.The change ofmiRNA-375 expressionmay
be associated with cancer diagnosis and prognosis, and miR-
375 could be a potential candidate target for cancer gene
therapy [16, 25].
This study further investigated the role of miR-375 in
regulating cell biological functions during the development
of LSCC. We found that miR-375 significantly inhibited
cell proliferation, migration, and invasion, while promoting
apoptosis in two LSCC cell lines (SNU-46, SNU-899). Here
we first proposed that miR-375 may be one of tumor suppres-
sor genes in LSCC. To elucidate the molecular mechanism
of LSCC development, we used bioinformatics to predict
IGF1R as the target gene of miR-375. Although confirmed
in squamous cell carcinoma of the esophagus [24], the
relationship between miRNA and its target gene is affected
by cell types and cell microenvironment; thus the same
miRNAmayplay different roles in different cells [13].Weused
dual-luciferase reporter assay to confirm the binding sites
of miR-375 in the 3󸀠UTR region in IGF1R mRNA in LSCC
cell line SNU-46. qRT-PCR and western blotting were also
used to confirm the effect of miR-375 in inhibiting IGF1R at
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Figure 9: miR-375 overexpression regulated IGF1R signaling. AKT mRNA levels were determined by qRT-PCR and normalized to those
of GAPDH. (∗) Significant difference when compared with control (𝑃 < 0.05) (a). Levels of p-Akt and actin were detected by western blot
analysis (b).
both mRNA and protein levels. IGFIR is a member of the
family of tyrosine kinase receptors and shows high level of
expression in many tumor cells [28]. It is an important factor
for cell malignant transformation [28–30]. Latest studies
have suggested that overexpression of IGF1R in the blood
of LSCC patients may serve as an independent indicator for
tumor recurrence and poor prognosis [31]. IGF1R mediates
a variety of important molecular signaling pathways via
its adaptor protein IRS and plays a key role in regulating
tumor development. Akt pathway is considered to be closely
related to the development of head and neck squamous cell
carcinoma [32, 33]. Interestingly, we found that not only the
expression of IGF1R in LSCC tissues was significantly higher
than the adjacent tissues, but also the levels of p-AKTmRNA
and protein in LSCC cells with miR-375 overexpression
were significantly decreased the same as the expression level
of IGF1R. These results suggest that miR-375/IGF1R/AKT
signaling pathway may play an important role in the devel-
opment of LSCC. Further studies are required to confirm the
mechanism.
In summary, this study has suggested that upregulation
of IGF1R due to miR-375 depletion is an important molec-
ular event in the development and progression of LSCC.
miR-375 can significantly inhibit LSCC cell proliferation,
migration, and invasion and promote apoptosis to suppress
tumor via IGF1R-mediated AKT signaling pathway. Thus,
miR-375 and IGF1R as the upstream molecules in AKT
signaling pathway may serve as a novel therapeutic target for
LSCC.
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